+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Osteoporosis Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4986955
  • Report
  • March 2021
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 5


  • Actavis plc
  • Amgen, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
The osteoporosis drugs market was valued at USD 10.66 billion in 2020, and it is poised to grow at a CAGR of 3.4% during the forecast period, 2021-2026, to reach USD 13.04 billion by 2026.

Multiple therapeutic regimens are being followed across the world in order to find a reliable treatment for Covid-19. Several research studies suggested that apart from drugs used for anti-viral treatments, other drugs such as osteoporosis drugs may also prove helpful in COVID-19 treatment which may likely boost the market. For instance, as per the study published in 2020 " Common osteoporosis treatment may help in reducing the incidence of COVID-19", reported that treatment such as denosumab, zoledronate, and calcium, used for the treatment of osteoporosis, could protect against COVID-19 as well. The research was conducted by Pompeu Fabra University, the Hospital del Mar Medical Research Institute (IMIM) and the Pere Virgili Health Park. As per the study, treatments with osteoporosis drugs could result in a 30 to 40 per cent reduction in the rate of COVID-19 infection. Thus, the studied market is likely to have positive impact of COVID-19.

The major factor accrediting to the growth of the market is increasing the incidence of osteoporosis. According to the National Osteoporosis Foundation, in 2018, an estimated 10 million have osteoporosis and another 44 million have low bone density, placing them at increased risk, in America. The rising geriatric population globally who are prone to low bone density is another main factor for the growth of the market. For instance, as per the data published by Internation Osteoporosis Foundation in 2020, 1 in 5 men and 1 in 3 women, over age 50, will experience osteoporosis fractures in their remaining lifetimes across the globe.

Furthermore, the growing investments in research and development by biotechnology and pharmaceutical companies are boosting the market growth. For instance, in October 2020, Italian pharmaceutical regulatory agency granted permission for human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may also help reduce COVID-19 symptoms and make patients less infectious. Thus, positive results from clinical trials may lead to the new treatment options thereby boosting the market growth in upcoming future. However, stringent regulations by the government are the major drawback for the market growth.

Key Market Trends

RANK Ligand Inhibitors Segment is Expected To Dominate the Market and Expected To Continue The Same Over Forecast Period

RANK ligand (RANKL) inhibitors are used for the management of osteoporosis in patients at high risk for bone fractures. The high growth possibility achieved is a result of positive patient results associated with rank ligand inhibitors. The positive patient outcomes can be credited to significant improvements in bone metabolism. Rank ligand inhibitors can also be utilized in combination with other drugs to impart a synergistic effect in the overall treatment regime. The above-mentioned factor is also anticipated to be one of the key factors accountable to present profitable opportunities. Other advantages relating to rank ligand inhibitors such as reduced cell bone turnover and increased bone mineral density, thereby implicating high demand.

RANK ligand may be effective as prophylaxis for COVID-19. As per the study conducted at the Hospital Del Mar, a general hospital in Spain in 2020, reported that denosumab targets the RANK/RANKL system which is involved in the maintenance of balance in the skeletal system. It is involved in lymph node development T cell activation and also affects the immune system. Inhibition of this system reduces pro-inflammatory cytokines in the body and helps in controlling inflammation, which is one of the major causes of life-threatening COVID-19. Thus, owing to the broaden application of RANKL the segment is likely to grow at faster pace.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall osteoporosis drugs market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of osteoporosis patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market.

In the North American region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing patient pool in the country and several collaborative efforts commenced by major companies to enhance their abilities and guarantee high medical standards. For instance, as per the data published by the National Osteoporosis Foundation (NOF) as of 2020, more than around 10 million people in the U.S. were suffering from osteoporosis which is most common in women who have gone through menopause. Thus, an upsurge in incidence as a result of menopause in women is anticipated to be a key growth contributing factor to the regional osteoporosis drug market.

COVID-19 is disrupting and delaying the treatment of many patients with osteoporosis, thus the American Society for Bone and Mineral Research (ASBMR) set up a steering committee of bone specialists to manage the treatment of targeted disorders amid pandemic. For instance, in April 2020, a paper on the evidence behind the recommendations has recently been published in the American Society for Bone and Mineral Research (ASBMR) official journal, the Journal of Bone and Mineral Research. The guidelines recommended that the patients should continue osteoporosis medications when possible to do so safely and that initiation of new oral bisphosphonate therapy can be done remotely and should not be delayed in patients at high risk for fracture. Thus, covid is expected to have profound impact on the regional market growth.

The increasing demand is also predicted to be a consequence of collaborative research initiatives implemented by the major healthcare organizations and companies and new product development consistently striving to improve treatment alternatives in the current market space. For instance, in 2019, Amgen announced that the U.S. Food and Drug Administration approved its Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). This will opens up the growth horizon to the regional market.

Competitive Landscape

The Osteoporosis Drugs market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Pfizer, Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co., Inc., Amgen, Inc., Radius Health, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis International AG, Actavis plc. This industry is anticipated to witness intense competition during the forecast period as a consequence of the rising incorporation of collaborative strategies amongst the key players to sustain in the competitive position. The other strategies incorporated are high R&D investment, mergers & acquisitions, and agreements for drug development.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • Actavis plc
  • Amgen, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Osteoporosis
4.2.2 Rise in the Geriatric Populations
4.3 Market Restraints
4.3.1 Stringent regulatory environment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Type
5.1.1 Parathyroid Hormone Therapy
5.1.2 Bisphosphonates
5.1.3 Calcitonin
5.1.4 RANKL Inhibitors
5.1.5 Others
5.2 By Application
5.2.1 Primary Osteoporosis
5.2.2 Secondary Osteoporosis
5.3 Geography
5.3.1 North America United States (By Drug Type, and By Application) Canada (By Drug Type, and By Application) Mexico (By Drug Type, and By Application)
5.3.2 Europe Germany (By Drug Type, and By Application) United Kingdom (By Drug Type, and By Application) France (By Drug Type, and By Application) Italy (By Drug Type, and By Application) Spain (By Drug Type, and By Application) Rest of Europe (By Drug Type, and By Application)
5.3.3 Asia-Pacific China (By Drug Type, and By Application) Japan (By Drug Type, and By Application) India (By Drug Type, and By Application) Australia (By Drug Type, and By Application) South Korea (By Drug Type, and By Application) Rest of Asia-Pacific (By Drug Type, and By Application)
5.3.4 Middle East and Africa GCC (By Drug Type, and By Application) South Africa (By Drug Type, and By Application) Rest of Middle East and Africa (By Drug Type, and By Application)
5.3.5 South America Brazil (By Drug Type, and By Application) Argentina (By Drug Type, and By Application) Rest of South America (By Drug Type, and By Application)

6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Eli Lily and Company
6.1.3 F. Hoffmann La Roche
6.1.4 Merck & Co., Inc.
6.1.5 Amgen, Inc.
6.1.6 Radius Health, Inc.
6.1.7 Teva Pharmaceutical Industries Ltd.
6.1.8 GlaxoSmithKline plc
6.1.9 Novartis International AG
6.1.10 Actavis plc

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Pfizer, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Radius Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Actavis plc
Note: Product cover images may vary from those shown
5 of 5